Abstract
The pharmacokinetics of enantiomers of pimobendan and their demethylated metabolites in plasma and red cells were studied in 8 normal healthy volunteers.
After racemic pimobendan 5 mg IV, the plasma concentration-time curve followed a two-compartment open-model with elimination half-lives of 1.81 h and 1.86 h for (+)- and (−)-pimobendan, respectively. The clearances and volumes of distribution postequilibrium were 13.5 ml · min−1 · kg−1, 14.4 ml · min−1 · kg−1; 1.74 l · kg−1 and 2.34 l · kg−1 for (+)- and (−)-pimobendan, respectively. Plasma protein binding (n=3) of (+)-, (−)-pimobendan, (+)- and (−)-demethylated metabolites was 97.6, 97.6, 92.2 and 92.5%, respectively. The plasma concentration-time curve also followed a two-compartment open model after oral administration of 7.5 mg racemic pimobendan. The absolute bioavailabilities of (+)- and (−)-pimobendan were 0.51 and 0.55. Peak levels of (+)-and (−)-pimobendan, both at 1.2 h, were 15.8 and 16.8 ng · ml−1, respectively. The (+)- and (−)-pimobendan concentrations in red cells were determined and their pharmacokinetics were estimated using red blood cell data. Interesting phenomena were observed: the peak concentrations of (+)- and (−)-pimobendan in red blood cells were about 5.5- and 9.2-times higher than in plasma, and the AUCs were correspondingly elevated. The volume of distribution of the central compartment of (−)-pimobendan in red cell was significantly smaller than that of (+)-pimobendan. (0.24 vs. 0.42 l · kg−1.) Similar phenomena were found after IV administration.
These all indicated stereoselective partitioning or distribution of (−)-pimobendan into red cells. Since the elimination half-life of (+)- and (−)-pimobendan in red cells was similar (3.07 vs 2.97 h), the highly significant difference in clearance between (+)- and (−)-pimobendan (3.7 vs 2.3 ml · min−1 · kg−1) was solely due to the stereoselective distribution of (−)-pimobendan into the red blood cells. This stereoselective property of the (−)-isomer may be the explanation of a previous report that (−)-pimobendan produced a 1.5-times larger contractile force in detergent-skinned preparations of cardiac muscle from guinea pig and dog than the (+)-isomer.
Similar content being viewed by others
References
Chu KM, Shieh SM, Wu SH, Hu OYP (1992) Enantiomeric separation of a cardiotonic agent pimobendan and its major active metabolite, UD-CG212 BS, by coupled achiral chiral normal-phase high-performance liquid chromatography. J Chromatogr Sci 30: 171–176
Clifton GD, Pennell AT, Harrison MR (1990) Pharmacodynamics of propranolol on left ventricular function: assessment by Doppler echocardiography. Clin Pharmacol Ther 48: 431–438
Drayer DE (1986) Pharmacodynamic and pharmacokinetic differences between drug enantiomers in humans: An overview. Clin Pharmacol Ther 40: 125–133
Endoh M, Shibasaki T, Satoh H, Norota I, Ishihata A (1991) Different mechanisms involved in the positive inotropic effects of benzimidazole derivative UD-CG 115 BS (pimobendan) and its demethylated metabolite UD-CG 212 Cl in canine ventricular myocardium. J Cardiovasc Pharmacol 17: 365–375
Fujino K, Sperelakis N, Solaro RJ (1988a) Differential effects of d- and l-pimobendan on cardiac myofilament calcium sensitivity. J Pharmacol Exp Ther 247: 519–523
Fujino K, Sperelakis N, Solaro RJ (1988b) Sensitization of dog and guinea pig heart myofilaments to Ca2+ activation and the inotropic effect of pimobendan: comparison with milrinone. Circ Res 63: 911–922
Hagemeijer F, Brand HJ, Roth W (1989) Cardiovascular effects and plasma level profile of pimobendan (UD-CG 115 BS) and its metabolite UD-CG 212 in patients with congestive heart failure after single and repeated oral dosing. J Cardiovasc Pharmacol 14: 302–310
Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, Roden DM (1989) Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 79: 1068–1076
Lalonde RL, O'Rear TL, Wainer IW, Drda KD, Herring VL, Bottorff MB (1990) Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective diposition. Clin Pharmacol Ther 48: 509–519
Levy RH, Boddy AV (1991) Stereoselectivity in pharmacokinetics: a general theory. Pharmacol Res 8: 551–556
Maier-Lenz H, Thieme G, Muller U, Degen J (1985) Inotropic effects and pharmacokinetics of pimobendan after single oral doses. J Clin Pharmacol 25: 472
Rüegg JC (1986) Effects of new inotropic agents on Ca++ sensitivity of contractile proteins. Circulation 73: III78-III84
Rüegg JC, Pfitzer G, Eubler D, Zeugner C (1984) Effect on contractility of skinned fibres from mammalian heart and smooth muscle by a new benzimidazole derivative, 4,5-dihydro- 6-[2-(4-methoxyphenyl)-1H-benzimidazol-5-yl]-5-methy 1–3(2H)-pyridazinone. Arzneimittelforschung/Drug Res 34:1736–1738
Schmitz W, von der Leyen H, Meyer W, Neumann J, Scholz H (1989) Phosphodiesterase inhibition and positive inotropic effects. J Cardiovasc Pharmacol 14: s11-s14
Scholz H, Meyer W (1986) Phosphodiesterade-inhibiting properties of newer inotropic agents. Circulation 73: III99-II108
Sedman AJ, Wagner JG (1976) CSTRIP, a FORTRAN IV computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci 65: 1006–1010
Sheiner LB (1985) Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters. J Pharmacokinet Biopharm 13: 515–540
Sheiner LB, Beal SL (1985) Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 13: 185–201
Verdouw PD, Hartog JM, Duncker DJ, Roth W, Saxena PR (1986) Cardiovascular profile of pimobendan, a benzimidazole-pyridazinone derivative with vasodilating and inotropic properties. Eur J Pharmacol 126: 21–30
Vogelgesang B, Echizen H, Schmidt E, Eichelbaum M (1984) Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 18: 733–740
von Meel JC (1985) Cardiovascular effects of the positive inotropic agents pimobendan and sulmazole in vivo. Arzneimittelforschung/Drug Res 35: 284–288
Walter M, Liebens I, Goethals H, Renard M, Dresse A, Bernard R (1988) Pimobendane (UD-CG 115 BS) in the treatment of severe congestive heart failure. An acute haemodynamic crossover and double-blind study with two different doses. Br J Clin Pharmacol 25: 323–329
Weiner DL (1986) NONLIN84/PCNONLIN: software for the statistical analysis of nonlinear models. Methods Find Exp Clin Pharmacol 8: 625–628
Williams KM, Lee EJ (1985) Importance of drug enantiomers in clinical pharmacology. Drugs 30: 333–354
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Chu, K.M., Shieh, S.M. & Hu, O.Y.P. Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese. Eur J Clin Pharmacol 47, 537–542 (1995). https://doi.org/10.1007/BF00193708
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00193708